Helper T-Cells vs. HIV
By Sean Henahan, Access Excellence
Boston, MA (11/21/97)- The identification of a part of
the human immune response capable of stopping the human immunodeficiency
virus (HIV) in its tracks appears to offer an important new research avenue
in the fight against AIDS.
In
most cases, the HIV virus dismantles the very immune cells that should
be stopping it. However, since the dawn of the AIDS epidemic in the early
1980's, researchers have noticed that a very small percentage of patients
who become infected with HIV do not go on to develop AIDS. These patients,
called long-term non-progressors, have long been considered a hopeful sign
that there is some potential for the human immune system to control HIV
infection.
Click Image for HIV Replication
Info.
Researchers from the Massachusetts General Hospital have now identified
a mechanism of immune activity in long-term non-progressors that appears
to suppress replication of HIV. Their research shows that the immune
systems of these patients produce large numbers of helper T cells
specifically targeted to HIV. Previous studies of individuals infected
with HIV have found very few or none of these virus-specific helper cells,
which animal studies have suggested are important in controlling many types
of viral infections.
"One of the biggest mysteries in our understanding of AIDS and HIV has
been why the immune responses that usually control viral infections don't
work," says Bruce Walker, MD, director of the Partners AIDS Research Center.
"Our work now suggests a simple explanation for how HIV escapes the normal
immune response, why the immune system slowly but inexorably breaks down,
and why a very small group of people have been able to avoid getting sick
from this virus."
Helper T cells are the central organizers of the entire immune system.
Individual helper cells target specific antigens- the protein signatures
of viruses, bacteria, tumors or other disease-causing entities. All helper
cells are vulnerable to infection by HIV, and AIDS develops when so many
helper cells have been infected and destroyed that the entire immune system
breaks down.
Usually when a virus invades the body, helper T cells that recognize
that virus's antigens become activated and reproduce in great numbers.
Not only does this proliferation of helper cells direct the immune response
to suppress the original infection, but the immune system keeps making
virus-specific cells to deal with any recurrence of the same infection.
Since proliferation of HIV-specific helper T cells had never been previously
observed, some scientists thought the virus somehow avoided all recognition
by helper cells. The new research shows that, in rare instances, HIV-specific
helper cells are generated and may be able to keep viral levels under control.
The initial clues came from studies of a long-term non-progressor who
has been infected with HIV for more than 18 years with no evidence of illness.
Although the presence of HIV antibodies proves he is infected with the
virus, the amount of virus in his blood has remained so low as to be undetectable,
even though he has never been treated with antiviral drugs. When the researchers
exposed samples of his blood to several HIV-specific antigens, they observed
something totally new. "Not only did this individual have HIV-specific
helper cells, but he had a huge helper-cell response, the first such response
we had ever seen to HIV," Walker says.
The researchers then looked for helper-cell responses in samples from
ten patients with new and active HIV infections. Tests conducted before
the patients started antiviral therapy showed a strong correlation between
levels of virus and helper-cell response: those with the strongest HIV-specific
T-cell response had the lowest viral loads, while those with higher viral
levels showed weaker T-cell responses.
"We began to develop a theory about why these virus-specific cells usually
don't appear in HIV-infected people," says Eric Rosenberg, MD. "Perhaps
the very helper cells capable of recognizing HIV were being destroyed in
the earliest stage of infection. We wondered if antiviral treatment at
that time might keep these helper cells from being eliminated."
The research team were soon able to test this hypothesis. Rosenberg
saw a patient with symptoms of acute HIV infection -- fever, severe sore
throat, rash and swollen lymph nodes who had been exposed to HIV only a
few days before. Rosenberg ran blood tests that revealed high levels of
virus but no antibody in the patient's blood, confirming a very recent
infection. The patient was given powerful antiviral drugs, and his viral
loads dropped dramatically to virtually undetectable levels while his immune
system began to generate a strong HIV-specific helper T-cell response.
Similar treatment in two other recently-infected individuals produced the
same responses. In people infected for longer periods -- six months or
more -- treatment did reduce viral levels but did not produce the helper
T-cell response seen in those treated immediately after infection.
"This suggests that there is a window of time -- and we don't know yet
how large it is -- during which we might be able to salvage the helper
T-cell response through vigorous antiviral treatment," Walker says. "So
it could be critically important for physicians to be alert for the symptoms
of acute HIV infection and, in those patients who appear at risk, to test
for the presence of virus." Walker stresses that preservation of the helper
T-cell response probably requires beginning treatment immediately after
infection, and he emphasizes that his team has not yet proven that this
response is solely responsible for controlling virus levels. Except for
the known long-term nonprogressors, all of the individuals participating
in this study continue to receive antiviral therapy. It also will be important,
he adds, to determine whether induction of this helper cell response in
persons who lack it would lead to more effective immune control of the
virus. Recent studies have shown that the virus persists in the body in
spite of potent antiviral therapy. Whether the immune response to the virus
can be augmented to provide additional benefit remains an open question.
The research appeared in the November 21, 1997 issue of Science
|
|